Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI
Por um escritor misterioso
Descrição
In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.
Tibsovo Approved for Treatment of Acute Myeloid Leukemia
Clinical Trial Results National Cancer Institute
Cancer Currents: An NCI Cancer Research Blog - NCI
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant
Revumenib Shows Promise in Acute Leukemia - CancerConnect
Chemo Shortage: 'Paycheck to Paycheck'; Cancer Blood Test Shines
Heather LaGrande on LinkedIn: Pembrolizumab for Advanced Triple
Cancer Currents: An NCI Cancer Research Blog - NCI
MEN1 mutations mediate clinical resistance to menin inhibition
Danielle Murphy, FNP-BC on LinkedIn: I am thrilled to announce I
